Merck KGaA (OTCMKTS:MKKGY) Posts Quarterly Earnings Results

Key Points

• Merck KGaA reported a quarterly earnings per share (EPS) of $0.57, exceeding analysts' expectations of $0.51 by $0.06.
• The company's revenue for the quarter reached $6.11 billion, significantly higher than the anticipated $5.34 billion.
• Following the earnings release, Merck KGaA's stock rose 3.5% to $25.39, with a 52-week trading range between $24.32 and $39.17.

Merck KGaA (OTCMKTS:MKKGY - Get Free Report) released its earnings results on Thursday. The company reported $0.57 EPS for the quarter, beating the consensus estimate of $0.51 by $0.06, Zacks reports. The firm had revenue of $6.11 billion for the quarter, compared to analysts' expectations of $5.34 billion. Merck KGaA had a net margin of 13.49% and a return on equity of 9.81%.

Merck KGaA Stock Up 3.5%

OTCMKTS:MKKGY traded up $0.85 during trading hours on Friday, reaching $25.39. The company's stock had a trading volume of 569,158 shares, compared to its average volume of 142,401. The business's 50-day moving average is $25.96 and its 200-day moving average is $27.27. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.31 and a quick ratio of 0.83. Merck KGaA has a one year low of $24.32 and a one year high of $39.17. The company has a market cap of $16.41 billion, a price-to-earnings ratio of 10.67, a price-to-earnings-growth ratio of 1.96 and a beta of 0.91.

Merck KGaA Company Profile

Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.